Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Portfolio Pulse from Nicolás Jose Rodriguez
Roy Bingham, CEO of BDSA, projects the U.S. cannabis market to reach nearly $46 billion by 2028, driven by adult-use and medical market expansion. The DEA's reclassification of cannabis to Schedule III is expected to spur medical research and investment, with significant growth anticipated in pharmaceutical applications and medical cannabis products. This rescheduling may reduce financial pressures on cannabis businesses and attract investment from healthcare and pharmaceutical companies. Despite federal restrictions, the shift is seen as an opportunity for healthcare and pharmaceutical industries to invest in cannabinoid research, potentially impacting medication use and fostering innovation in the sector.
May 14, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie Inc., with its synthetic cannabinoid product Marinol, may see increased opportunities and interest in its cannabinoid-based treatments following the DEA's cannabis rescheduling.
AbbVie's existing involvement in cannabinoid-based treatments through Marinol positions it to potentially benefit from the increased focus and investment in cannabinoid research following the DEA's decision.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Amyris, Inc.'s use of synthetic biology to produce cannabinoids may gain significant momentum from the DEA's rescheduling, enhancing its position in sustainable and pure cannabinoid product development.
Amyris, Inc.'s innovative approach to producing cannabinoids through fermentation processes is likely to benefit from the DEA's rescheduling, as it could lead to increased research, development, and investment in sustainable cannabinoid products.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 75
POSITIVE IMPACT
Corbus Pharmaceuticals' focus on cannabinoid receptor type 2 agonists for treating inflammatory and fibrotic diseases may receive a significant boost from the DEA's rescheduling, enhancing its research and development prospects.
Given Corbus Pharmaceuticals' specialization in developing therapeutics using cannabinoid receptor type 2 agonists, the DEA's rescheduling is likely to positively impact its R&D efforts by facilitating more research and potentially attracting investment.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 75
POSITIVE IMPACT
Cardiol Therapeutics' focus on cannabidiol-based therapies for heart diseases could see enhanced research opportunities and investment interest following the DEA's cannabis rescheduling.
The DEA's rescheduling of cannabis may provide Cardiol Therapeutics, with its focus on cannabidiol-based anti-inflammatory therapies, increased opportunities for research and investment, potentially accelerating its development programs.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 70
POSITIVE IMPACT
Zynerba Pharmaceuticals' development of synthetic cannabinoid therapeutics for neuropsychiatric conditions could benefit from the DEA's rescheduling, potentially accelerating research and development.
The DEA's decision to reclassify cannabis could positively impact Zynerba Pharmaceuticals by facilitating more research into synthetic cannabinoid therapeutics, potentially speeding up development and approval processes.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 70
POSITIVE IMPACT
Jazz Pharmaceuticals' acquisition of GW Pharmaceuticals positions it strongly in the growing cannabis market, potentially benefiting from the DEA's rescheduling and increased research and investment in the sector.
Jazz Pharmaceuticals' strategic acquisition of GW Pharmaceuticals, a leader in developing FDA-approved CBD medication, places it at a significant advantage to capitalize on the expanding cannabis market and the DEA's recent rescheduling.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Intec Pharma's innovative oral drug delivery systems for cannabinoid-based therapies could see increased development opportunities and market interest following the DEA's cannabis rescheduling.
The DEA's rescheduling of cannabis may positively impact Intec Pharma by increasing interest and investment in its innovative oral drug delivery systems for cannabinoid-based therapies, potentially accelerating development and commercialization.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 70
POSITIVE IMPACT
Pfizer's acquisition of Arena Pharmaceuticals, with its cannabinoid-based therapeutic pipeline, aligns well with the growing interest and investment in cannabis research, potentially boosting its R&D efforts.
Pfizer's acquisition of Arena Pharmaceuticals, which includes a focus on cannabinoid-based therapeutics, places Pfizer in a strong position to capitalize on the increased research and investment opportunities following the DEA's cannabis rescheduling.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80